Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.

Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic. The resulting candidate ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Durable reprogramming of human T cells may now be possible thanks to a new technique based on the CRISPRoff and CRISPRon methodology. Researchers from the Arc Institute, Gladstone Institutes, and the ...

T cells are the immune system’s frontline fighters. When they detect danger, they rapidly multiply and transform into effector cells that destroy pathogens. This transformation demands an intense ...